Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Kane Biotech Inc. V.KNE

Alternate Symbol(s):  KNBIF

Kane Biotech Inc. is a Canada-based biotechnology company. The Company is engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. It has a portfolio of biotechnologies and products, which includes StrixNB, DispersinB, Aledex, bluestem, bluestem, silkstem, goldstem, coactiv+, coactiv+, DermaKB and DermaKB Biofilm. Its... see more

TSXV:KNE - Post Discussion

Kane Biotech Inc. > Kane latest presentation (Dec.16th,2020) - Link
View:
Post by francoisl13 on Dec 17, 2020 2:37pm

Kane latest presentation (Dec.16th,2020) - Link

This biotech is very well managed (I said it many times over the last few years and it's true...).
Please find a link below to the latest presentation from Kane, you will find new information in regards to development and date target at which Kane wants to hit the market with their products (including DispersinB)....very interesting....especially when knowing that they rarely miss their targets. 
Kane Presentation (Dec. 16th 2020)
Love the potential. GLTA
Comment by lscfa on Dec 18, 2020 11:44am
By Q2 2021 Kane will sign a partnership with US co. where US co. will pay $7 million Cdn to Kane for a 10% ownership in the partnership valuing this part of Kane business at $70 million.  Projecting $2M in revenues in 2022 and growing to $30M by 2025.
Comment by MirrorWorldMan on Dec 21, 2020 10:46pm
Its nice to be invested in a solid well resourced Canadian BioTech company with solid transparent partner deals in place and products that are commercialized, with rigid business plans and financing to make it work. A solid niche to make it work into the future and continual interest from identified sources that have committed stated dollar amounts in the years ahead...eh?
Comment by StoneMan45 on Dec 30, 2020 7:06pm
actually states ..."DispersinB® Wound Care biofilm wash      PMA or BLA 1st Wound Care Bioburden claims        Launching in 2022 2024 Sales projections expected to top $25M USD.." that is 2024 (not 2025) and at current exchange rates that would be 32 million CND. The projected revenue is specific to the DispersinB Wound Care Biofilm Wash ...more  
Comment by lscfa on Dec 30, 2020 7:39pm
So slides 8 and 14 differ. Which is correct?    
Comment by StoneMan45 on Dec 31, 2020 9:27am
you are correct... either way it's a win but I'm hoping page 8
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities